Persones / Equip Humà

Susana Rives Solà

Buscador de publicacions

Publicacions

  • Ortíz-Maldonado V, Rives-Solà S, Castellà M, Alonso-Saladrigues A, Benítez-Ribas D, Caballero-Baños M, Baumann T, Jordi Cid Colom, Garcia-Rey E, Llanos C, Torrebadell-Burriel M, Villamor N, Giné E, Díaz-Beyá M, Guardia L, Montoro M, Català-Temprano A, Faura A, González EA, Español-Rego M, Klein-González N, Alsina L, Castro P, Jordán-García I, Fernández S, Ramos F, Suñé G, Perpiñá U, Canals JM, Lozano M, Trias E, Scalise A, Varea S, Sáez-Peñataro J, Torres F, Calvo G, Esteve J, Urbano-Ispizua Á, Juan-Otero M and Delgado J.

    CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+Relapsed/Refractory Malignancies

    MOLECULAR THERAPY . 29(2): 636-644. Nº de cites: 88

    [doi:10.1016/j.ymthe.2020.09.027]

  • Deyà-Martinez A, Alonso-Saladrigues A, García, AP, Faura, A, Torrebadell-Burriel M, Vlagea, A, Català-Temprano A, Esteve-Solé A, Juan-Otero M, Rives-Solà S and Alsina L.

    Kinetics of humoral deficiency in CART19-treated children and young adults with acute lymphoblastic leukaemia

    BONE MARROW TRANSPLANTATION . 56(2): 376-386. Nº de cites: 12

    [doi:10.1038/s41409-020-01027-6]

  • Buechner J, Grupp SA, Hiramatsu H, Teachey DT, Rives-Solà S, Laetsch TW, Yanik GA, Wood P, Awasthi R, Yi L, Chassot-Agostinho A, Eldjerou LK and De Moerloose B.

    Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy

    blood advances . 5(2): 593-601. Nº de cites: 35

    [doi:10.1182/bloodadvances.2020002757]

  • Levine JE, Grupp SA, Pulsipher MA, Dietz AC, Rives-Solà S, Myers GD, August KJ, Verneris MR, Buechner J, Laetsch TW, Bittencourt H, Baruchel A, Boyer MW, De Moerloose B, Qayed M, Davies SM, Phillips CL, Driscoll TA, Bader P, Schlis K, Wood PA, Mody R, Yi L, Leung M, Eldjerou LK, June CH and Maude SL.

    Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia

    Journal for ImmunoTherapy of Cancer . 9(8): 2287. Nº de cites: 37

    [doi:10.1136/jitc-2020-002287]

  • Vega-García N, Benito R, Esperanza-Cebollada E, Llop M, Robledo C, Vicente-Garces C, Alonso J, Barragán E, Fernandez-Isern G, Hernández-Sánchez JM, Martín-Izquierdo M, Maynou-Fernández J, Minguela A, Montaño A, Ortega M, Torrebadell-Burriel M, Cervera J, Sánchez J, Jiménez-Velasco A, Riesco S, Hernández-Rivas JM, Lassaletta Á, Fernández JM, Rives-Solà S, Dapena JL, Ramírez M and Camós-Guijosa M.

    Helpful Criteria When Implementing NGS Panels in Childhood Lymphoblastic Leukemia

    Journal of Personalized Medicine . 10(4): 244. Nº de cites: 1

    [doi:10.3390/jpm10040244]

  • Fuster JL, Molinos-Quintana A, Fuentes C, Fernández JM, Velasco P, Pascual T, Rives-Solà S, Dapena JL, Sisinni L, López-Godino O, Palomo P, Villa-Alcázar M, Bautista F, González-Vicent M, López-Duarte M, García-Morín M, Ramos-Elbal E and Ramírez M.

    Blinatumomab and inotuzumab for B cell precursor acute lymphoblastic leukaemia in children: a retrospective study from the Leukemia Working Group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP)

    BRITISH JOURNAL OF HAEMATOLOGY . 190(5): 764-771. Nº de cites: 20

    [doi:10.1111/bjh.16647]

  • Mirones I, Moreno L, Patiño-García A, Lizeaga G, Moraleda JM, Toribio ML and Pérez-Martínez A.

    Inmunoterapia con células CAR-T en hematooncología pediátrica.

    ANALES DE PEDIATRIA . 93(1): . Nº de cites: 1

    [doi:10.1016/j.anpedi.2019.12.014]

  • Hrusak O, Kalina T, Wolf J, Balduzzi A, Provenzi M, Rizzari C, Rives-Solà S, Del Pozo Carlavilla M, Alonso MEV, Domínguez-Pinilla N, Bourquin JP, Schmiegelow K, Attarbaschi A, Grillner P, Mellgren K, van der Werff Ten Bosch J, Pieters R, Brozou T, Borkhardt A, Escherich G, Lauten M, Stanulla M, Smith O, Yeoh AEJ, Elitzur S, Vora A, Li CK, Ariffin H, Kolenova A, Dallapozza L, Farah R, Lazic J, Manabe A, Styczynski J, Kovacs G, Ottoffy G, Felice MS, Buldini B, Conter V, Stary J and Schrappe M.

    Flash survey on severe acute respiratory syndrome coronavirus-2 infections in paediatric patients on anticancer treatment

    EUROPEAN JOURNAL OF CANCER . 132: 11-16. Nº de cites: 130

    [doi:10.1016/j.ejca.2020.03.021]

  • Castella M, Caballero-Baños M, Ortiz-Maldonado V, González-Navarro EA, Suñé G, Antoñana-Vidósola A, Boronat A, Marzal B, Millán L, Martín-Antonio B, Jordi Cid Colom, Lozano M, García E, Tabera J, Trias E, Perpiña U, Canals JM, Baumann T, Benítez-Ribas D, ELENA CAMPO, Yagüe-Ribes J, Urbano-Ispizua Á, Rives-Solà S, Delgado J and Juan-Otero M.

    Point-Of-Care CAR T-Cell Production (ARI-0001) Using a Closed Semi-automatic Bioreactor: Experience From an Academic Phase I Clinical Trial

    FRONTIERS IN IMMUNOLOGY . 11: 482-482. Nº de cites: 85

    [doi:10.3389/fimmu.2020.00482]

  • Laetsch TW, Myers GD, Baruchel A, Dietz AC, Pulsipher MA, Bittencourt H, Buechner J, De Moerloose B, Davis KL, Nemecek E, Driscoll T, Mechinaud F, Boissel N, Rives-Solà S, Bader P, Peters C, Sabnis HS, Grupp SA, Yanik GA, Hiramatsu H, Stefanski HE, Rasouliyan L, Yi L, Shah S, Zhang J and Harris AC.

    Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial

    LANCET ONCOLOGY . 20(12): 1710-1718. Nº de cites: 65

    [doi:10.1016/S1470-2045(19)30493-0]